Arexvy RSV expansion 18-49 at-risk; Shingrix benefits
Key Questions
What is the expanded approval for Arexvy?
FDA approved Arexvy on March 13 for adults 18-49 at risk and those 50-59. This expands options alongside existing approvals for older adults.
What benefits have been confirmed for Shingrix?
Shingrix benefits for dementia and heart health have been reconfirmed, with experts recommending the two-dose series starting at age 50. Uptake has declined 17%.
What is the status of RSV prefusion F vaccines?
The adult prefusion F protein vaccine route has reached saturation with three FDA approvals. This has led to increased price competition in the market.
FDA Arexvy Mar13 for 18-49 at-risk + 50-59; Shingrix dementia/heart reconfirmed, uptake -17%; maternal Abrysvo 85%. RSV prefusion F saturation with price competition.
Sources (2)
Updated May 23, 2026